Hard to Treat Diseases Inc. (HTDS)

Market Cap	5.82K
Revenue	6.16M
Net Income	974.30K
Shares Out	5.82B
EPS	0.00
PE Ratio	0.01
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,000
Average Volume	852,837
Open	0.0000
Previous Close	n/a
Day's Range	0.0000 - 0.0000
52-Week Range	n/a
Beta	0.92
RSI	51.46
Earnings Date	n/a

About Hard to Treat Diseases

Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: HTDS